Patent intelligence · US
US 11752202
Compositions and methods for treating hemoglobinopathies
Compositions and methods for treating hemoglobinopathies
Patent details — US 11752202
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 12, 2023
- Expiration
- Sep 7, 2043
- Applicant
- Beam Therapeutics Inc.
- Claims
- 28
- CPC classes
- A61K, A61K31/7088, A61K35/15, A61K35/18
Quick answer
US 11752202 (Compositions and methods for treating hemoglobinopathies) is held by Beam Therapeutics Inc.. Status: granted. Granted Sep 12, 2023. Expires Sep 7, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Beam Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/7088, A61K35/15, A61K35/18, A61K35/28, A61K38/465
More from Beam Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12296053
Nanomaterials comprising triols
granted -
US 12268753
Nanomaterials comprising a biodegradable feature
granted -
US 12133884
Methods of substituting pathogenic amino acids using programmable base editor systems
granted -
US 12059477
Nanomaterials
granted -
US 12016908
Compositions and methods for treating hemoglobinopathies
granted -
US 11795443
Uses of adenosine base editors
granted -
US 11594345
Method for producing Ac-225 from Ra-226
granted
Frequently asked questions
What is US patent 11752202?
US 11752202 (Compositions and methods for treating hemoglobinopathies) is held by Beam Therapeutics Inc.. Status: granted. Granted Sep 12, 2023. Expires Sep 7, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11752202?
Beam Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11752202 expire?
Our index shows an expiration date of Sep 7, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.